These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33658322)

  • 1. Potential Role of CHI3L1+ Astrocytes in Progression in MS.
    Cubas-Núñez L; Gil-Perotín S; Castillo-Villalba J; López V; Solís Tarazona L; Gasqué-Rubio R; Carratalá-Boscá S; Alcalá-Vicente C; Pérez-Miralles F; Lassmann H; Casanova B
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33658322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
    Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.
    Boesen MS; Jensen PEH; Magyari M; Born AP; Uldall PV; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2018 Aug; 24():175-183. PubMed ID: 30055504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D
    PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF chitinase 3-like-1 association with disability of primary progressive MS.
    Pérez-Miralles F; Prefasi D; García-Merino A; Gascón-Giménez F; Medrano N; Castillo-Villalba J; Cubas L; Alcalá C; Gil-Perotín S; Gómez-Ballesteros R; Maurino J; Álvarez-García E; Casanova B
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32611760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining active progressive multiple sclerosis.
    Sellebjerg F; Börnsen L; Ammitzbøll C; Nielsen JE; Vinther-Jensen T; Hjermind LE; von Essen M; Ratzer RL; Soelberg Sørensen P; Romme Christensen J
    Mult Scler; 2017 Nov; 23(13):1727-1735. PubMed ID: 28831853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
    De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
    Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes.
    Vu L; An J; Kovalik T; Gendron T; Petrucelli L; Bowser R
    J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):350-358. PubMed ID: 31937582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
    Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
    Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.
    Engel S; Friedrich M; Muthuraman M; Steffen F; Poplawski A; Groppa S; Bittner S; Zipp F; Luessi F
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):. PubMed ID: 31454774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 14. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.
    Matute-Blanch C; Villar LM; Álvarez-Cermeño JC; Rejdak K; Evdoshenko E; Makshakov G; Nazarov V; Lapin S; Midaglia L; Vidal-Jordana A; Drulovic J; García-Merino A; Sánchez-López AJ; Havrdova E; Saiz A; Llufriu S; Alvarez-Lafuente R; Schroeder I; Zettl UK; Galimberti D; Ramió-Torrentà L; Robles R; Quintana E; Hegen H; Deisenhammer F; Río J; Tintoré M; Sánchez A; Montalban X; Comabella M
    Brain; 2018 Apr; 141(4):1085-1093. PubMed ID: 29452342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    Burman J; Raininko R; Blennow K; Zetterberg H; Axelsson M; Malmeström C
    J Neuroimmunol; 2016 Mar; 292():52-7. PubMed ID: 26943959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
    Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
    Peng L; Bi C; Xia D; Mao L; Qian H
    Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.
    Talaat F; Abdelatty S; Ragaie C; Dahshan A
    Neurol Sci; 2023 Sep; 44(9):3243-3252. PubMed ID: 36988727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.